1[2]Watanabe Y, Hayashi Y, Shimizu J, et al. Mediastinal nodal in volvement and the prognosis of non small cell lung cancer. Chest,1991,100(2): 422-428.
2[4]Kris MG, Martini N, Gralla RJ, et al. Primary chemotherapy instage Ⅲ A non-small cell lung cancer patients with clinically appar ent mediastinal lymph node metastases: focus on five-year survi vors. LungCancer,1993,9: 369-376.
3[5]Okada M, Tsubota N, Yoshimura M, et al. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multi ple stations. Chest,2000,118(1) : 123-128.
4[6]Nakanishi R, Osaki T, Nakanishi K, et al. Treatment strategy for patients with surgically discovered N2 stage Ⅲ A non small cell lung cancer. Ann Thorac Surg, 1997,64(2): 342-348.
5[7]Ichinose Y, Kato H, Koike T, et al. Completely resected stage Ⅲ A non-small cell lung cancer: the significance of primary tumor lo cation and N2 station. J Thorac Cardiovasc Surg, 2001,122 (4): 803-808.
6[9]Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase Ⅲ trial of the Southern It aly Cooperative Oncology Group. J Clin Oncol,2000,18(7): 1451- 1457.
7[10]Kourousis C, Androulakis N, Kakolyris S, et al. First-line treat ment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer, 1998,83(10) : 2083-2090.
8[11]Oral EN, Bavbek S, Kizir A, et al. Preliminary analysis of a phase Ⅱ study of Paclitaxel and CHART in locally advanced non-small cell lung cancer. LungCancer,1999,25(3): 191-198.
9[12]Henschke CI. Early lung cancer action project: overall design and findings from baseline screening. Cancer, 2000, 89 ( 11 Suppl) : 2474-2482.
